Pancreatic Cancer Research

Clinical trialPhase 1Unknown

Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors

First-in-human (FIH), Open-Label, Phase 1a (Dose Escalation)/Phase 1b (Expansion Cohort) Trial of BJ-001 as a Single Agent and in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Solid Tumors

Outcome
Outcome unknown
Phase
Phase 1
Status
Unknown
Study type
Interventional
Start
4 December 2019
Listed end
22 October 2024
Enrollment
92 participants
Sites
5
Primary outcomes
Frequency of adverse events (AEs) and SAE; Severity of AEs in patients with solid tumors enrolled in the study.; Dose limiting toxicities (DLTs) BJ-001 as a single agent; Dose limiting toxicities (DLTs) BJ-001 in combination with pembrolizumab inhibitor.
Sponsor type
Industry
Results posted
No
Last update
9 November 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to assess the safety and tolerability of BJ-001, a human IL-15 fusion protein, administered via subcutaneous injections, as a single agent and in combination with pembrolizumab in adult patients with Locally Advanced/Metastatic Solid Tumors